Session Abstract – PMWC 2023 Silicon Valley

Showcase Track S1 - January 27 9.45 A.M.-10.00 A.M.

The PMWC 2023 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.

  • Emerging Therapeutics/Cell Therapy
  • Emerging Therapeutics/CVD
  • Emerging Therapeutics/Gene Therapy
  • Emerging Therapeutics/Immunotherapy
  • Emerging Therapeutics/Radiation Therapy

Confirmed Presenting Companies:

 Speaker Profile

Ph.D., Founder & Chief Strategy Officer, Atreca, Inc.

Dr. Serafini is one of the three principal founders of Atreca and was CEO from the company’s inception in 2010 until 2018. In his role as Chief Strategy Officer, Dr. Serafini is responsible directly for research, preclinical development, technology, and intellectual property. Before co-founding Atreca, he was Chief Scientific Officer of Nuon Therapeutics, a development-stage biotechnology company. Previously, Dr. Serafini was a founder of Renovis, a public biotechnology company, where he served as an executive officer in multiple technical and business management roles, including leading the research and M&A functions. Prior to founding Renovis, Dr. Serafini was an award-winning faculty member in the Department of Molecular and Cell Biology at the University of California, Berkeley, where he established the university’s Functional Genomics Laboratory.

Emerging Therapeutics Showcase:
Atreca, Inc.

Atreca is a clinical-stage biotechnology company inverting the traditional approach to cancer drug discovery. Atreca’s unique platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors.

The Next Frontier of Therapeutic Antibodies
Addressing unmet medical need in oncology and identifying novel targets at a more rapid pace.

 Speaker Profile

MA, Chief Commercial Officer, Adaptive Biotech

Nitin Sood currently leads the MRD business at Adaptive Biotechnologies. He has a wealth of experience in commercial expansion, product development and building successful businesses at leading life science and diagnostic companies, with a focus on the application of NGS in medicine and research. Recently, he was Sr. Vice President of Product at Guardant Health where he led the commercial expansion of the company’s oncology portfolio to cover advanced and early-stage cancers, including the launch of Guardant Reveal for solid tumor MRD. Prior to that he was CEO of NuGEN, a leader in NGS sample prep. His experience also includes leading global businesses at PerkinElmer and Agilent Technologies, where he held GM roles spanning a portfolio of products in genomics, pathology, and pre-clinical research. He holds master’s degrees in both computer science and molecular biology from Ball State University and Delhi University.

Emerging Therapeutics Showcase:
Adaptive Biotech

Adaptive Biotechnologies is a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease.

Transforming Care for Lymphoid Cancer Patients Using MRD
We will discuss promising work in MRD: recent data, KOL perspectives, and how MRD transforms patient care.

 Speaker Profile

Ph.D., CEO, Mekonos

Anil Narasimha is the co-founder and CEO of Mekonos. He is a scientist by training, having done his graduate work at UC San Diego and a postdoctoral fellowship with Dr. Michael Snyder at Stanford University. His expertise lies in enabling technologies in cell and gene therapy, and he co-founded Mekonos in hopes of making delivery of molecules more efficient, precise, and automated.

Emerging Therapeutics Showcase:

Mekonos is an enabling technology company developing a platform for ex-vivo delivery of molecules into cells.

Ex-vivo Delivery of Payloads into Cells using Silicon Technology
Mekonos is a Series A company developing a platform for precise delivery of payloads into cells.